<p>Cell were exposed to MMS (A), H<sub>2</sub>O<sub>2</sub> (B), low (C) and high (D) doses of 5-FU, MMC (E) and UVB (F) assessed by the MTT assay. Viability curves showed that the Melphalan-resistant cells are cross-resistant to MMS, H<sub>2</sub>O<sub>2</sub>, low dose 5-FU and MMC. Conversely, high dose of 5-FU affects the proliferation of resistant cells in higher extent compared to sensitive cells. Exposure to UVB similarly affected growth of both cell lines. Increasing absorbance correlates directly with the number of living cells. Standard deviation bars are indicated.</p
<p>(A, B) Growth curve analysis (A) and viability (B) of the RPMI-shDEK and U266-shDEK cells are sho...
<p><b>A</b>) HOB were exposed to melphalan [50 µg/ml], VP-16 [50 µM] or rTGF-β1 [10 ng/ml] for 24 ho...
<p>The relative sensitivity of a panel of melanoma cells lines containing V600E BRAF mutations was d...
<p>Cell growth rate (A) and cell cycle distribution (B) of sensitive (8226) and resistant (LR5) cell...
Isolated limb perfusion with melphalan is a long-standing treatment for melanoma but the clinical co...
<p>(A) The chemosensitive (Nt, Nw) and resistant (B1Q and B1V) cell lines were treated with 0–10 μg/...
<p>(A) Quantitative western blot analysis revealed that the NHEJ proteins DNA ligase IV, XRCC4 and R...
Through exposure to melphalan or taxol, four novel multidrug resistant variants of the human nasal c...
Methotrexate (MTX) and N-(phosphonacetyl)- -aspartate (PALA) are two agents to which cellular resist...
<p>MA cells and the SUM149-Luc parental cell line were simultaneously treated with various anticance...
<p>Levels of DNA glycosylases (A), relative UDG activities (B) and genomic 8-oxodG-content in sensit...
Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It ...
<p>(A) The number of γ-H2AX foci per cell nucleus (N>13) was manually quantified for each time point...
<div><p>In a conceptual study of drug resistance we have used a preclinical model of malignant B-cel...
In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines ...
<p>(A, B) Growth curve analysis (A) and viability (B) of the RPMI-shDEK and U266-shDEK cells are sho...
<p><b>A</b>) HOB were exposed to melphalan [50 µg/ml], VP-16 [50 µM] or rTGF-β1 [10 ng/ml] for 24 ho...
<p>The relative sensitivity of a panel of melanoma cells lines containing V600E BRAF mutations was d...
<p>Cell growth rate (A) and cell cycle distribution (B) of sensitive (8226) and resistant (LR5) cell...
Isolated limb perfusion with melphalan is a long-standing treatment for melanoma but the clinical co...
<p>(A) The chemosensitive (Nt, Nw) and resistant (B1Q and B1V) cell lines were treated with 0–10 μg/...
<p>(A) Quantitative western blot analysis revealed that the NHEJ proteins DNA ligase IV, XRCC4 and R...
Through exposure to melphalan or taxol, four novel multidrug resistant variants of the human nasal c...
Methotrexate (MTX) and N-(phosphonacetyl)- -aspartate (PALA) are two agents to which cellular resist...
<p>MA cells and the SUM149-Luc parental cell line were simultaneously treated with various anticance...
<p>Levels of DNA glycosylases (A), relative UDG activities (B) and genomic 8-oxodG-content in sensit...
Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It ...
<p>(A) The number of γ-H2AX foci per cell nucleus (N>13) was manually quantified for each time point...
<div><p>In a conceptual study of drug resistance we have used a preclinical model of malignant B-cel...
In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines ...
<p>(A, B) Growth curve analysis (A) and viability (B) of the RPMI-shDEK and U266-shDEK cells are sho...
<p><b>A</b>) HOB were exposed to melphalan [50 µg/ml], VP-16 [50 µM] or rTGF-β1 [10 ng/ml] for 24 ho...
<p>The relative sensitivity of a panel of melanoma cells lines containing V600E BRAF mutations was d...